L'intérêt à découvert pour KalVista Pharma donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de KalVista Pharma. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

KalVista Pharma (NASDAQ:KALV) Stock, Rapport sur les intérêts à découvert

KALVISTA PHARMACEUTICALS INC

KalVista Pharma

KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States. The company is also conducting preclinical development on a novel, oral, Factor XIIa inhibitor program.

KalVista Pharmaceuticals, Inc. - Common Stock

KalVista Pharmaceuticals Inc

UBS analyst Alex Kramm maintains Moodys (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCO#NYSE">MCO</a>) with a Neutral and raises the price target from $445 to $515.

News

Price Target

Analyst Ratings

UBS Maintains Neutral on Moodys, Raises Price Target to $515

Orion Plans To Discontinue Production At Three To Five Of Its Carbon Black Lines At Multiple Facilities In Americas And EMEA By 2025 End

As Amphenol Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APH#NYSE">APH</a>) trades near its 52-week high, the company finds itself at a pivotal moment in an ever-evolving tech landscape. With a 42% surge in stock value this year, outpacing the broader S&amp;P 500 Information Technology Sector Index, Amphenol&#8217;s recent fiscal first-quarter results reveal robust demand for its advanced interconnect solutions, particularly in burgeoning markets such as IT <a href="https://www.benzinga.com/topic/technology-stocks">datacom and mobile devices.</a>
Amphenol designs, manufactures, and markets advanced interconnect, sensor, and antenna solutions worldwide. The company offers a range of products, including electrical, electronic, and fiber optic connectors, antennas, sensors, and specialty cables, for automotive, aerospace, communications, and industrial applications.
Also Read: <a target="_blank" href="https://www.benzinga.com/tech/25/05/45261116/cisco-unveils-quantum-chip-and-lab-to-push-next-gen-networking" rel="noreferrer noopener">Cisco Unveils Quantum Chip And Lab To Push Next-Gen Networking</a>
On April 23, Amphenol reported <a href="https://www.benzinga.com/news/earnings/25/04/44950358/amphenol-q1-earnings-48-topline-growth-driven-by-it-mobile-defense-sectors" target="_blank" rel="noreferrer noopener">fiscal first-quarter 2025</a> sales growth of 48% year-over-year to $4.81 billion, surpassing the analyst consensus estimate of $4.23 billion and the company&#8217;s estimate of $4.00 billion to $4.10 billion. On Jan. 22, the company reported <a href="https://www.benzinga.com/news/earnings/25/01/43130244/amphenol-q4-earnings-30-sales-growth-ceo-highlights-growth-in-it-mobile-and-defense-markets-forecasts-strong-q1-sales-growth" target="_blank" rel="noreferrer noopener">fourth-quarter topline</a> growth of 30% Y/Y to $4.32 billion, topping the analyst consensus estimate of $4.07 billion. 
Organic growth in the IT datacom market and robust organic growth in the mobile devices, defense, and communications networks markets, together with contributions from the company&#8217;s acquisition program, drove the topline growth. The adjusted operating margin for the quarter reached a record 21.3%, up from 21.0% in the same quarter last year.
Amphenol expects second-quarter sales to be between $4.90 billion and $5.00 billion. This represents a 36%-39% increase over the prior-year quarter, and the street view pegs expectations at $4.58 billion.
On March 17, JPMorgan analyst Samik Chatterjee flagged Amphenol as one of the companies <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/03/44362565/why-nvidias-next-moves-matter-for-amphenol-dell-super-micro" target="_blank" rel="noreferrer noopener">poised to benefit</a> from Nvidia Corp&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) Blackwell Ultra ramp. While the adoption of optics remains a concern, analysts expect copper to continue dominating in-rack connectivity—a positive sign for Amphenol. Amphenol, with its intense exposure to passive copper, along with Coherent (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COHR#NYSE">COHR</a>), Fabrinet (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FN#NYSE">FN</a>), and Lumentum Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LITE#NASDAQ">LITE</a>), is likely to draw attention as the AI wave builds, according to the analyst.
Nineteen analysts have set a <a target="_blank" href="https://www.benzinga.com/quote/APH/analyst-ratings" rel="noreferrer noopener">consensus price target</a> of $92.50 for Amphenol. Recent ratings from Goldman Sachs, Evercore ISI Group, and UBS average a target of $104.33, indicating a potential upside of 5.55% for the stock.
Price Action: APH stock is down 0.23% to $98.32 during early trading on Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46278679/will-recent-events-dent-palantir-technologies-stock-385-growth" target="_blank" rel="noreferrer noopener">Will Recent Events Dent Palantir Technologies Stock 385% Growth?</a></li>
</ul>
Photo: Shutterstock

Tech

COHR

LITE

NVDA

Amphenol Soars 42% To 52-Week High Riding AI Wave

UBS analyst Robin Farley maintains Las Vegas Sands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LVS#NYSE">LVS</a>) with a Neutral and raises the price target from $43 to $48.

UBS Maintains Neutral on Las Vegas Sands, Raises Price Target to $48

UBS analyst Rodrigo Alcantara maintains Coca-Cola Femsa SAB de (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KOF#NYSE">KOF</a>) with a Buy and raises the price target from $109 to $113.

UBS Maintains Buy on Coca-Cola Femsa SAB de, Raises Price Target to $113

UBS analyst Alex Kramm maintains Intercontinental Exchange (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ICE#NYSE">ICE</a>) with a Buy and raises the price target from $195 to $210.

UBS Maintains Buy on Intercontinental Exchange, Raises Price Target to $210

<ul>
<li>Real-world and implementation data describe effectiveness of long-acting Vocabria + Rekambys (cabotegravir + rilpivirine LA (CAB+RPV LA)) for HIV treatment and assess experiences of using Apretude (cabotegravir long-acting (CAB LA) for PrEP)in range of populations</li>
<li>New phase IIIb data look at preferences among treatment-naive adults offered the choice to switch to CAB+RPV LA after attaining rapid viral suppression with Dovato (DTG/3TC) daily oral therapy</li>
<li>Interim data from wave three of the Positive Perspectives study demonstrate impact of joint decision-making on HIV treatment satisfaction and health outcomes</li>
</ul>
ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced the presentation of abstracts from its innovative HIV treatment and prevention portfolio at the International AIDS Society 2025 Conference (IAS 2025) in Kigali, Rwanda. Key data will highlight the long-term effectiveness of Vocabria &amp; Rekambys, (branded as Cabenuva in the US, Canada and Australia) the company's complete long-acting injectable regimen for treatment; evaluate patient preference for long-acting injectables compared to daily oral therapy; and measure benefits of long-acting injectables in tackling common challenges associated with taking daily pills, including stigma and adherence.

Biotech

General

ViiV Healthcare Showcases Data At IAS 2025 Highlighting Long-Term Effectiveness And Patient Preference For Long-Acting HIV Injectables Vocabria + Rekambys And Apretude Over Daily Oral Therapy

UBS analyst Batya Levi maintains Crown Castle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCI#NYSE">CCI</a>) with a Buy and raises the price target from $118 to $124.

UBS Maintains Buy on Crown Castle, Raises Price Target to $124

UBS analyst Thomas Wadewitz maintains ArcBest (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARCB#NASDAQ">ARCB</a>) with a Neutral and raises the price target from $64 to $84.

ARCB

UBS Maintains Neutral on ArcBest, Raises Price Target to $84

Wolfspeed Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOLF#NYSE">WOLF</a>) shares are climbing on Tuesday after nearly doubling on Monday. Here&#8217;s a look at what&#8217;s driving the <a href="https://www.benzinga.com/trading-ideas/movers/25/07/46279362/wolfspeed-wolf-stock-is-exploding-higher-monday-whats-going-on">continued momentum</a>. 
What To Know: Wolfspeed shares have soared in recent sessions as investors anticipate a potential turnaround for the company after it filed for <a href="https://www.benzinga.com/trading-ideas/movers/25/07/46194475/why-wolfspeed-stock-is-ripping-higher-today">Chapter 11 bankruptcy</a> last week. 
Wolfspeed said it expects to emerge from the restructuring process with 70% less debt, representing a reduction of approximately $4.6 billion. The company believes it will be better positioned to focus on long-term growth and accelerate its path to profitability, and investors are buying in. 
Wolfspeed on Monday announced that it appointed Gregor van Issum as CFO, effective Sept. 1. The announcement sparked some investor optimism with shares closing the session up 95.8% at $2.31. 
Van Issum has more than 20 years of experience in tech-focused transformational restructuring and strategic financing. He previously held senior roles at semiconductor manufacturers ams-OSRAM AG and NXP Semiconductors N.V.
&#8220;Gregor has helped lead large, multibillion euro businesses with complex manufacturing operations, which will be invaluable to Wolfspeed as we unlock the potential of our purpose-built 200mm platform. The Board and I look forward to collaborating with Gregor as we position Wolfspeed for long-term growth and profitability,&#8221; said Robert Feurle, CEO of Wolfspeed. 
The CFO addition comes after the company named David Emerson as COO in May as part of the company&#8217;s leadership refresh. Wolfspeed said last week that&nbsp;it will continue to operate normally while it goes through its restructuring, delivering silicon carbide materials and devices to customers.&nbsp;The company expects to emerge from the restructuring process by the end of the third quarter.
WOLF Price Action: <a href="http://benzinga.com/quote/WOLF" target="_blank" rel="noreferrer noopener">Wolfspeed shares</a> were up 36.9% at $3.19 at the time of publication Tuesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>. 
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/07/46290622/openai-sticks-with-nvidia-chatgpt-maker-says-no-plans-to-use-googles-ai-chips-at-scale">OpenAI Sticks With Nvidia: ChatGPT Maker Says No Plans To Use Google&#8217;s AI Chips At Scale</a></li>
</ul>
Photo: T. Schneider/Shutterstock.com

Movers

WOLF

Wolfspeed Stock Continues To Surge: What's Driving The Momentum?

UBS analyst Batya Levi maintains American Tower (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMT#NYSE">AMT</a>) with a Buy and raises the price target from $250 to $260.

UBS Maintains Buy on American Tower, Raises Price Target to $260

AppLovin Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) shares are moving higher Tuesday. The company&#8217;s subsidiary Wurl announced a collaboration with Amazon&#8217;s Prime Video. Here&#8217;s what you <a href="https://www.benzinga.com/quote/APP/analyst-ratings">need to know</a>.
What To Know: Wurl on Tuesday said it teamed up with Prime Video to support the portfolio of live TV channels available for Prime members in Germany, helping with the launch of the Prime channel. 
The new live TV channel will leverage Wurl&#8217;s Global FAST Pass solution for the launch and focus on premium Prime Video entertainment. Wurl will also help Prime Video monetize its channel and access data to help the company better understand and retain viewers. 
"Prime Video is leading the way in helping to accelerate the industry by bringing premium live entertainment content to audiences – and we're thrilled to be working alongside them to make that happen,&#8221; said Keith Bedford, General Manager, EMEA at Wurl. 
AppLovin shares also appear to be getting a boost on Tuesday from positive <a href="https://www.benzinga.com/analyst-stock-ratings">analyst coverage</a> from Scotiabank. 
Scotiabank analyst Nat Schindler initiated coverage on AppLovin with a Sector Outperform rating and set a price target of&nbsp;$430 late Monday. The analyst highlighted three main points driving the initiation, including the company&#8217;s AXON engine, AppLovin&#8217;s expansion to smaller brands and its first-party data and on-device footprint through its software development kit. 
Schindler said the company is positioned to become an &#8220;indispensable&#8221; infrastructure layer for digital marketing through performance advertising, adding that AppLovin is an &#8220;at-scale walled garden&#8221; for in-app ads, which gives the company pricing power.
&#8220;Seldom does a company come around that operates in such rarefied air that not only has it blown through the Rule of 40 into the triple digits (EBITDA margin plus revenue growth), but the number keeps growing as the company gets more efficient,&#8221; the Scotiabank analyst wrote in the note. 
AppLovin has a Street-high target of $650 and is well off its 52-week highs of $525.15, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>. The company has been <a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/45910389/short-seller-says-applovin-is-desperate-and-doomed-shares-slide">targeted</a> by multiple short sellers this year. 
APP Price Action: <a href="http://benzinga.com/quote/APP">AppLovin shares</a> were up 2.55% at $353.80 at the time of publication Tuesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/large-cap/25/07/46247962/21-billion-in-4-days-amazon-prime-day-set-to-go-beast-mode-and-its-stock-might-join-the-party">$21 Billion In 4 Days? Amazon Prime Day Set To Go Beast Mode—And Its Stock Might Join the Party</a></li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/initiation/25/07/46294493/this-circle-internet-analyst-begins-coverage-on-a-bearish-note-here-are-top-5-initiations-for-tuesday">This Circle Internet Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Tuesday</a></li>
</ul>
Photo: Shutterstock.

Initiation

AppLovin Stock Is Rising Tuesday: What's Going On?

Wells Fargo analyst Joseph Quatrochi maintains MKS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MKSI#NASDAQ">MKSI</a>) with a Equal-Weight and raises the price target from $85 to $100.

MKSI

Wells Fargo Maintains Equal-Weight on MKS, Raises Price Target to $100

Wells Fargo analyst Joseph Quatrochi maintains Lam Research (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRCX#NASDAQ">LRCX</a>) with a Equal-Weight and raises the price target from $75 to $95.

LRCX

Wells Fargo Maintains Equal-Weight on Lam Research, Raises Price Target to $95

Wells Fargo analyst Joseph Quatrochi maintains Applied Mat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAT#NASDAQ">AMAT</a>) with a Overweight and raises the price target from $200 to $215.

AMAT

Wells Fargo Maintains Overweight on Applied Mat, Raises Price Target to $215

Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) is <a href="https://www.benzinga.com/topic/nvidia" target="_blank" rel="noreferrer noopener">trading close</a> to its 52-week high of $161 on Tuesday. The stock has seen a notable increase this year, rising almost 18% year-to-date and gaining over 64% in market value in the last three months. 
This performance surpasses the broader market, as the S&amp;P 500 and NASDAQ Composite indexes have generated approximately 6% in returns year-to-date.
In May, Nvidia reported <a target="_blank" href="https://www.benzinga.com/markets/tech/25/06/46177736/what-is-going-on-with-nvidia-stock" rel="noreferrer noopener">first-quarter revenue</a> of $44.1 billion, a 69% increase year-over-year and a 12% sequential rise. This figure exceeded the Street consensus estimate of $43.2 billion, despite a new export ban impacting sales of its chips to China, one of its significant markets.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/06/45845825/ai-momentum-powers-nvidia-arm-and-chip-supply-chain-in-bofa-recap" rel="noreferrer noopener">AI Momentum Powers Nvidia, Arm And Chip Supply Chain In BofA Recap</a>
<h2 class="wp-block-heading">Recent Key Events Impacting Valuation</h2>
Several recent events have influenced Nvidia&#8217;s valuation. On July 4, 2025, President Donald Trump unveiled the &#8220;<a target="_blank" href="https://www.benzinga.com/markets/tech/25/07/46291393/micron-stock-soars-42-in-2025-but-ceo-warns-of-demand-pull-ins" rel="noreferrer noopener">Big Beautiful Bill</a>,&#8221; which would raise the semiconductor investment tax credit from 25% to 30% through 2026, giving chipmakers more substantial incentives to expand U.S. manufacturing.
He also created the United States Investment Accelerator within the Commerce Department by executive order, shifting control of the CHIPS Act program directly under the White House.
Although Trump previously criticized the $39 billion in grants and $75 billion in loans under the CHIPS and Science Act, he now backs pro-chip policies through this bill, which has cleared the Senate and is awaiting a House vote.
Also in July, OpenAI <a target="_blank" href="https://www.benzinga.com/markets/equities/25/07/46290622/openai-sticks-with-nvidia-chatgpt-maker-says-no-plans-to-use-googles-ai-chips-at-scale" rel="noreferrer noopener">confirmed it will</a> continue using Nvidia AI chips at scale, rejecting Alphabet&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) Google&#8217;s tensor processing units (TPUs) despite a recent cloud deal with Google Cloud. Nvidia, in turn, reaffirmed its partnership with OpenAI, highlighting its role as the core hardware provider for OpenAI&#8217;s AI models.
<h2 class="wp-block-heading">Supply Chain And Export Controls</h2>
Reportedly, contract chipmaker and key Nvidia supplier Taiwan Semiconductor Manufacturing Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) has <a href="https://www.benzinga.com/markets/tech/25/07/46283410/taiwan-semiconductor-shifts-focus-100-billion-usa-expansion" target="_blank" rel="noreferrer noopener">accelerated its U.S. expansion</a>. This move is a response to Washington&#8217;s chip tariff policies, leading TSM to delay the construction of its second plant in Japan to prioritize its growing American footprint.
In March, TSM Chairman C.C. Wei announced an additional $100 billion U.S. investment, building on the $65 billion disclosed in April 2024. This expanded investment aims to boost domestic chipmaking to support major clients like Nvidia and Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) and reduce reliance on overseas production.
Meanwhile, the U.S. is drafting <a target="_blank" href="https://www.benzinga.com/markets/asia/25/07/46266218/us-plans-to-restrict-ai-chip-exports-to-malaysia-thailand-to-curb-diversion-to-china" rel="noreferrer noopener">new export controls</a> to prevent Nvidia AI chips from reaching China via third-party routes, specifically through Malaysia and Thailand. This marks the first formal step in Trump&#8217;s overhaul of prior AI chip export rules, though key security questions remain unresolved.
These U.S. sanctions had previously compelled Nvidia to halt H20 chip exports to China on April 9, resulting in a $4.5 billion first-quarter charge for Nvidia, attributed to excess inventory and purchase commitments. Consequently, Nvidia projected its second-quarter revenue at $45 billion, approximately $780 million below estimates, citing an $8 billion impact from lost H20 sales due to these export restrictions.
<h2 class="wp-block-heading">Analyst Projections</h2>
Thirty-seven analysts have set a <a target="_blank" href="https://www.benzinga.com/quote/NVDA/analyst-ratings" rel="noreferrer noopener">consensus price forecast</a> of $179.17 for Nvidia. Loop Capital issued the highest forecast at $250 on June 25, 2025, while Seaport Global gave the lowest at $100 on April 30, 2025. The latest ratings from Citigroup (July 7), Mizuho (July 3), and Loop Capital (June 25) average a forecast of $208.33, suggesting a potential upside of 30.65% for Nvidia based on those recent views.
NVDA Price Action: NVDA stock is trading higher by 0.82% to $159.59 premarket at last check Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/reiteration/25/07/46281768/telecom-stocks-are-no-longer-one-size-fits-all-analyst-says-heres-which-company-stands-out" target="_blank" rel="noreferrer noopener">Telecom Stocks Are No Longer One-Size-Fits-All, Analyst Says — Here&#8217;s Which Company Stands Out</a></li>
</ul>
Image by Jack Hong via Shutterstock

AAPL

GOOG

GOOGL

Nvidia Outpaces Market With AI-Powered Growth, Nears Record Highs

DeFi Development Corp. (NASDAQ:<a href="https://www.benzinga.com/stock/DFDV#NASDAQ">DFDV</a>) (the "Company") the first public company with a treasury strategy built to accumulate and compound Solana ("SOL"), announced today the purchase of 47,272 Solana ("SOL") at an average purchase price of $149.09 and valued at approximately $7.03 million. Following the transaction, DeFi Development Corp. now holds a total of approximately 690,420 SOL and SOL equivalents, valued at approximately $102.7 million, inclusive of staking rewards. The latest purchase marks a +64.1% increase in the Company's SOL and SOL equivalent holdings compared to 420,690 SOL held 60 days prior.

DFDV

DeFi Development Purchases 47,272 Solana At Average Price Of $149.09 And Valued At ~$7.03M

Craig-Hallum analyst Anthony Stoss maintains Enovix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENVX#NASDAQ">ENVX</a>) with a Buy and raises the price target from $12 to $15.

ENVX

Craig-Hallum Maintains Buy on Enovix, Raises Price Target to $15

Wells Fargo analyst Joseph Quatrochi maintains ASML Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASML#NASDAQ">ASML</a>) with a Overweight and raises the price target from $840 to $890.

ASML

Wells Fargo Maintains Overweight on ASML Holding, Raises Price Target to $890

Wells Fargo analyst Ken Gawrelski maintains Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) with a Overweight and raises the price target from $664 to $783.

Wells Fargo Maintains Overweight on Meta Platforms, Raises Price Target to $783

Press Releases

KalVista Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

KalVista Pharmaceuticals Medical Congress Presentations Highlight Potential of Sebetralstat to Redefine Hereditary Angioedema Management

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

KalVista Pharmaceuticals to Present New Sebetralstat Data at the European Academy of Allergy and Clinical Immunology Congress 2025

KalVista Pharmaceuticals Announces FDA Will Not Meet PDUFA Goal Date for Sebetralstat NDA for Hereditary Angioedema Due to FDA Resource Constraints

KalVista Pharmaceuticals Presents New Data at the European Academy of Allergy and Clinical Immunology Congress 2025 on the Efficacy of Sebetralstat for the On-demand Treatment of HAE Attacks Among Patients Receiving Long-Term Prophylaxis

Comments

KalVista Pharma

Intérêt court

KalVista Pharma (NASDAQ:KALV) Stock, Rapport sur les intérêts à découvert

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL